From Financial Modeling Prep: 2025-03-06 07:00:05

Karyopharm Therapeutics Inc. is a pharmaceutical company focused on developing drugs for cancer treatment, with XPOVIO as its primary product for multiple myeloma. However, the company’s ROIC is -123.21%, lower than its WACC of 8.77%, indicating inefficiency in capital utilization and a concern for investors compared to peers.

MacroGenics, another player in the pharmaceutical industry, also faces negative returns with a ROIC of -53.63% and a WACC of 12.09%. Despite challenges, MacroGenics’ situation is less severe than Karyopharm’s, suggesting a slightly better position in the market.

TG Therapeutics stands out among peers with a positive ROIC of 7.85% and a WACC of 15.27%, indicating efficient capital utilization. This makes TG Therapeutics a more attractive option for investors compared to Karyopharm and other companies struggling with negative returns.

Heron Therapeutics, Intra-Cellular Therapies, and Agios Pharmaceuticals also have negative ROICs, reflecting the industry-wide challenge of generating returns above their cost of capital. With WACC figures and ROIC to WACC ratios indicating struggles in capital utilization, these companies face similar issues in the competitive landscape.



Read more at Financial Modeling Prep:: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Financi…